Outpatient Oncology Infusion Market Size Report, 2035

Outpatient Oncology Infusion Market - By Product, By Application, By Therapy, By Mode - Global Forecast, 2026 - 2035

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Global

1.3.2&nbsp;&nbsp;&nbsp; Regional/Country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional trends

2.2.2&nbsp;&nbsp;&nbsp; Product trends

2.2.3&nbsp;&nbsp;&nbsp; Application trends

2.2.4&nbsp;&nbsp;&nbsp; Therapy trends

2.2.5&nbsp;&nbsp;&nbsp; Mode trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising prevalence of cancer across the globe

3.2.1.2&nbsp;&nbsp;&nbsp; Increasing preference for cost-effective outpatient care

3.2.1.3&nbsp;&nbsp;&nbsp; Technological advancements in infusion pumps

3.2.1.4&nbsp;&nbsp;&nbsp; Surging government initiatives for cancer awareness

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High costs of cancer therapies

3.2.3&nbsp;&nbsp;&nbsp; Opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Adoption of smart infusion pumps with EHR interoperability

3.2.3.2&nbsp;&nbsp;&nbsp; Development of biosimilars to reduce treatment costs

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.4.1&nbsp;&nbsp;&nbsp; North America

3.4.2&nbsp;&nbsp;&nbsp; Europe

3.4.3&nbsp;&nbsp;&nbsp; Asia Pacific

3.4.4&nbsp;&nbsp;&nbsp; LAMEA

3.5&nbsp;&nbsp;&nbsp; Technology and innovation landscape

3.5.1&nbsp;&nbsp;&nbsp; Current technological trends

3.5.2&nbsp;&nbsp;&nbsp; Emerging technologies

3.6&nbsp;&nbsp;&nbsp; Value chain analysis

3.7&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.8&nbsp;&nbsp;&nbsp; Policy landscape

3.9&nbsp;&nbsp;&nbsp; Epidemiology scenario

3.10&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.11&nbsp;&nbsp;&nbsp; PESTEL analysis

3.12&nbsp;&nbsp;&nbsp; Gap analysis

3.13&nbsp;&nbsp;&nbsp; Future market trends

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Company market share analysis

4.3.1&nbsp;&nbsp;&nbsp; Global

4.3.2&nbsp;&nbsp;&nbsp; North America

4.3.3&nbsp;&nbsp;&nbsp; Europe

4.3.4&nbsp;&nbsp;&nbsp; Asia Pacific

4.3.5&nbsp;&nbsp;&nbsp; LAMEA

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Mergers &amp; acquisitions

4.6.2&nbsp;&nbsp;&nbsp; Partnerships &amp; collaborations

4.6.3&nbsp;&nbsp;&nbsp; New product launches

4.6.4&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Infusion pumps

5.3&nbsp;&nbsp;&nbsp; Intravenous sets

5.4&nbsp;&nbsp;&nbsp; IV cannulas

5.5&nbsp;&nbsp;&nbsp; Needleless connectors

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Lung cancer

6.3&nbsp;&nbsp;&nbsp; Liver cancer

6.4&nbsp;&nbsp;&nbsp; Breast cancer

6.5&nbsp;&nbsp;&nbsp; Prostate cancer

6.6&nbsp;&nbsp;&nbsp; Other cancers

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Therapy, 2021 - 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Chemotherapy

7.3&nbsp;&nbsp;&nbsp; Targeted therapy

7.4&nbsp;&nbsp;&nbsp; Immunotherapy

7.5&nbsp;&nbsp;&nbsp; Hormonal therapy

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Mode, 2021 - 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Intramuscular (IM)

8.3&nbsp;&nbsp;&nbsp; Intravenous (IV)

8.4&nbsp;&nbsp;&nbsp; Subcutaneous

8.5&nbsp;&nbsp;&nbsp; Other modes

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Netherlands

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.6&nbsp;&nbsp;&nbsp; MEA

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

9.6.4&nbsp;&nbsp;&nbsp; Nigeria

9.6.5&nbsp;&nbsp;&nbsp; Egypt

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; B. Braun

10.2&nbsp;&nbsp;&nbsp; Baxter

10.3&nbsp;&nbsp;&nbsp; Becton, Dickinson and Company

10.4&nbsp;&nbsp;&nbsp; Fresenius Kabi

10.5&nbsp;&nbsp;&nbsp; ICU Medical

10.6&nbsp;&nbsp;&nbsp; IRADIMED

10.7&nbsp;&nbsp;&nbsp; Medtronic

10.8&nbsp;&nbsp;&nbsp; Micrel

10.9&nbsp;&nbsp;&nbsp; MOOG

10.10&nbsp;&nbsp;&nbsp; NIPRO

10.11&nbsp;&nbsp;&nbsp; Penlon

10.12&nbsp;&nbsp;&nbsp; Teleflex

10.13&nbsp;&nbsp;&nbsp; Terumo 
&nbsp;

Outpatient Oncology Infusion Market

Inquiry Before Buying